Mads Krogsgaard Thomsen, CSO at Novo Nordisk, will take up the position as CEO of the Novo Nordisk Foundation effective from 1 March 2021.

Austrian researchers have found that a lack of activation of the NK receptor is highly associated with severe COVID-19 disease courses.

Lund-based Abliva AB named Dr Ellen Donnelly as its new CEO. At the beginning of February she succeeded Dr Erik Kinnmann, who had been CEO since 2018.

Swiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.

Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.

A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells. 

Märta Segerdahl will take over the position as Chief Medical Officer of Swedish AlzeCure Pharma AB on April.

Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.
 

The association of a low HS-Omega-3 Index® and mortality from COVID-19 is analyzed in a comprehensive study with Munich hospital.

Cellink AB will take over all shares of Ginolis Oy, a Finnish company focusing on diagnostics automation and advanced robotics solutions for medical and diagnostic industries.